Araoka H, Fujii T, Izutsu K, Kimura M, Nishida A, Ishiwata K, Nakano N, Tsuji M, Yamamoto H, Asano-Mori Y, Uchida N, Wake A, Taniguchi S, Yoneyama A (2012) Rapidly progressive fatal hemorrhagic pneumonia caused by Stenotrophomonas maltophilia in hematologic malignancy. Transpl Infect Dis 14(4):355–363. https://doi.org/10.1111/j.1399-3062.2011.00710.x

Article  CAS  PubMed  Google Scholar 

Saburi M, Oshima K, Takano K, Inoue Y, Harada K, Uchida N, Fukuda T, Doki N, Ikegame K, Matsuo Y, Katayama Y, Ozawa Y, Matsuoka KI, Kawakita T, Mori Y, Ara T, Nakamae H, Kimura T, Kanda Y, Atsuta Y, Ogata M (2023) Risk factors and outcome of Stenotrophomonas maltophilia infection after allogeneic hematopoietic stem cell transplantation: JSTCT, transplant complications working group. Ann Hematol 102(9):2507–2516. https://doi.org/10.1007/s00277-023-05320-4

Article  CAS  PubMed  Google Scholar 

Karakonstantis S, Rousaki M, Vassilopoulou L, Kritsotakis EI (2024) Global prevalence of cefiderocol non-susceptibility in Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia: a systematic review and meta-analysis. Clin Microbiol Infect 30(2):178–188. https://doi.org/10.1016/j.cmi.2023.08.029

Article  CAS  PubMed  Google Scholar 

Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF (2017) In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant gram-negative Bacilli from North America and Europe, including carbapenem-nonsusceptible isolates (SIDERO-WT-2014 study). Antimicrob Agents Chemother 61(9). https://doi.org/10.1128/aac.00093-17

Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF (2018) In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of gram-negative Bacilli collected worldwide in 2014 to 2016. Antimicrob Agents Chemother 62(2). https://doi.org/10.1128/aac.01968-17

Yamano Y (2019) In Vitro Activity of Cefiderocol against a broad range of clinically important gram-negative bacteria. Clin Infect Dis 69(Suppl 7):S544–s551. https://doi.org/10.1093/cid/ciz827

Article  CAS  PubMed  PubMed Central  Google Scholar 

Biagi M, Vialichka A, Jurkovic M, Wu T, Shajee A, Lee M, Patel S, Mendes RE, Wenzler E (2020) Activity of cefiderocol alone and in combination with levofloxacin, minocycline, polymyxin B, or trimethoprim-sulfamethoxazole against multidrug-resistant stenotrophomonas maltophilia. Antimicrob Agents Chemother 64(9). https://doi.org/10.1128/aac.00559-20

Testing TECAS (2024) Guidance document on broth microdilution testing of cefiderocol.

CLSI (2023) Performance standards for antimicrobial susceptibility testing. CLSI supplement M100, 33rd edn. Clinical Laboratory Standards Institute, Wayne

Google Scholar 

Sakoh T, Kimura M, Takagi S, Ogura S, Morishima M, Yamamuro R, Yamaguchi K, Yuasa M, Kaji D, Kageyama K, Taya Y, Nishida A, Ishiwata K, Yamamoto H, Yamamoto G, Asano-Mori Y, Wake A, Uchida N, Taniguchi S, Araoka H (2023) Predictive scoring system for distinguishing Stenotrophomonas maltophilia bacteremia from Pseudomonas aeruginosa bacteremia in patients with hematological malignancies. Ann Hematol 102(5):1239–1246. https://doi.org/10.1007/s00277-023-05185-7

Article  CAS  PubMed  Google Scholar 

Matuschek E, Longshaw C, Takemura M, Yamano Y, Kahlmeter G (2022) Cefiderocol: EUCAST criteria for disc diffusion and broth microdilution for antimicrobial susceptibility testing. J Antimicrob Chemother 77(6):1662–1669. https://doi.org/10.1093/jac/dkac080

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bianco G, Boattini M, Comini S, Gaibani P, Cavallo R, Costa C (2024) Performance evaluation of Bruker UMIC(®) microdilution panel and disc diffusion to determine cefiderocol susceptibility in Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Achromobacter xylosoxidans and Burkolderia species. Eur J Clin Microbiol Infect Dis 43(3):559–566. https://doi.org/10.1007/s10096-024-04745-7

Article  CAS  PubMed  Google Scholar 

CLSI (2024) Performance standards for antimicrobial susceptibility testing. CLSI supplement M100, 34th edn. Clinical Laboratory Standards Institute, Wayne

Google Scholar